Merck Sharp + Dohme Corp.

Merck Sharp + Dohme B.v.

Abdul-Basit Alhassan

Sobhana Babu Boga

Xiaolei Gao

Alan B Cooper

Hugh Y Zhu

Gerald Wayne Shipps, Jr

Yongqi Deng

Liang Zhu

Hao Wu

Joseph Michael Kelly

Jian Liu

Chundao Yang

Jagdish A Desai

Shilan Liu

James J-s Wang

Xin Yao

Neng-Yang Shih

Joseph A Kozlowski

Wensheng Yu

Younong Yu

Sunil Paliwal

Rajan Anand

Hon-Chung Tsui

Deodial Guy Guiadeen

Ahmed Abdi Samatar

Yang Nan

Sie-Mun Lo

Ronald J Doll

James Han Wang

M Arshad Siddiqui

Vincent Stewart Madison

Kevin J Wilson

Phieng Siliphaivanh

Ronald M Kim

Alan W Hruza

Umar Faruk Mansoor

Tjeerd Barf

Li Xiao

Matthew H Daniels

Christian Fischer

Jayaram R Tagat

Binyuan Sun

Adrianus Petrus Antonius De Man

Dahai Wang

Robert Sun

Allard Kaptein

Corey E Bienstock

Mehul F Patel

Jiaqiang Cai

Arthur A Oubrie

Henry M Vaccaro

Christiaan Gerardus Johannes Maria Jans

Xiaohua Huang

Gerald W Shipps

Tong Wang

Johannes Bernardus Maria Rewinkel

Deodialsingh Guiadeen

Adam J Schell

Brendan O'Boyle

Jacobus C H M Wijkmans

Youhao Dong

Hans C A Raaijmakers

Azim Alan Celebi

Jan-Gerard Sterrenburg

Subrahmanyam Gudipati

Yiji Wu

Jyhshing Wang

Hans CA Raaijmakers

Corey Beinstock

Brendan M O'BOYLE

Adrianus PA De Man

Christiaan GJM Jans

Johannes BM Rewinkel

Jacobus CHM Wijkmans

Tjeerd A Barf

James Wang

James J-S Wang

Jagdish Desai

Mehul Patel

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

BTK inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

Benzamide imidazopyrazine Btk inhibitors

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. 

BTK Inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. 

Heterocyclic compounds as ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. 

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Growing community of inventors

Scotch Plains, NJ, United States of America

Abdul-Basit Alhassan